A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis.
Adolfo González Serrano, Marie Laurent, Thomas Barnay...
https://pubmed.ncbi.nlm.nih.gov/36306481/Actively Recruiting
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2016-08-31
3000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating cancer management in older adults, focusing on patients aged 70 years or older diagnosed with solid or hematologic cancers. The study explores how a comprehensive Geriatric Assessment GA can help oncologists make better treatment decisions by evaluating patients overall health, comorbidities, functional abilities, nutrition, cognition, mood, medications, and social support. This approach aims to address the challenges of treating elderly cancer patients who often have complex health status and varied needs. Participants receive an extensive GA conducted by geriatricians that covers nine key health domains, including functional status, mobility, nutrition, cognitive function, mood, comorbidities, polypharmacy, social environment, and incontinence. After this assessment, oncologists review and may adjust their initial treatment proposals based on the GA findings, typically within about two weeks. The study tracks treatment feasibility, chemotherapy toxicities, and overall survival at one and five years. During the study, participants undergo the GA evaluation and their treatment decisions are monitored through multidisciplinary meetings. Researchers collect data on chemotherapy side effects, treatment completion, and mortality over time, following patients for up to five years. The study involves ongoing observation without experimental treatments, focusing on how GA influences oncologist decisions and patient outcomes in routine clinical care.
CONDITIONS
Elderly CAncer Patient
P
PHILIPPE CAILLET, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
National Cancer Institute, France
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 2 weeks after initial oncologist treatment proposal
Participants undergo an extensive geriatric assessment evaluating multiple health domains such as functional status, mobility, nutrition, cognition, mood, comorbidities, medication use, social environment, and incontinence.
1 visit (in-person)
Duration - Up to approximately 6 months after inclusion
Participants receiving chemotherapy are monitored for treatment feasibility and toxicities throughout their chemotherapy treatment period.
Visits according to chemotherapy treatment schedule
Duration - Up to 5 years
Participants are followed for overall mortality and health status up to 5 years after inclusion.
Periodic follow-up visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Adolfo González Serrano, Marie Laurent, Thomas Barnay...
https://pubmed.ncbi.nlm.nih.gov/36306481/Claudia Martinez-Tapia, Thomas Diot, Nadia Oubaya...
https://pubmed.ncbi.nlm.nih.gov/32889525/Matthieu Frasca, Claudia Martinez-Tapia, Charline Jean...
https://pubmed.ncbi.nlm.nih.gov/39142494/Assistance Publique - Hôpitaux de Paris
Lead Sponsor
National Cancer Institute, France
Collaborating Sponsor